ArticleBMJ open2022

Therapy of genomic unstable solid tumours (WHO grade 3/4）in clinical stage III/IV using individualised neoantigen tumour peptides-INP trial (individualised neoantigen tumour peptides immunotherapy): study protocol for an open-label, non-randomised, prospective, single-arm trial.

Ling Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.